Thermo Fisher Scientific
Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.
Watch Now
Systechone
Serialization is a great achievement for our industry. However, most executives now realize that it is only part of the solution, and serialization alone cannot solve the escalating problems of counterfeiting and diversion within the pharmaceutical industry. The global value of pharmaceutical counterfeiting is $200B annually. More staggering is that the gray market is forecasted to reach almost $3 trillion by 2022.
Watch Now
In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.
Watch Now
This series will provide you with tools to critically process and analyze medical scientific literature. You will get a good understanding of basic statistical concepts and theory that enable you to explain, understand and interpret data. These Webinars are practical and based on published articles and the analysis of these.
Watch Now